Brief: Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation
08/09/2025 12:45
Sept 8 (Reuters) - Pasithea Therapeutics Corp KTTA.O: PASITHEA THERAPEUTICS ANNOUNCES ENROLLMENT OF COHORT 2 FOLLOWING POSITIVE SAFETY REVIEW COMMITTEE (SRC) RECOMMENDATION FOR ITS ONGOING PHASE 1/1B CLINICAL TRIAL OF PAS-004 IN ADULT NF1 PATIENTS PASITHEA THERAPEUTICS CORP - INTERIM DATA FROM FIRST TWO COHORTS EXPECTED Q1 2026 Source text: ID:nGNX994mnN Further company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement